Trial Profile
A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Zoligratinib (Primary)
- Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer; Uterine cancer
- Focus Adverse reactions; First in man
- Sponsors Debiopharm Group
- 08 Sep 2020 Status changed from active, no longer recruiting to discontinued.
- 31 May 2020 Results (n=18; data cutoff: 8 Oct 2018) of final analysis from expansion cohort part of the study presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 01 May 2020 Planned End Date changed from 1 Mar 2020 to 1 Sep 2020.